References
- Hinchey J, Chaves C, Appignani B, . A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494–500.
- Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. Am J Neuroradiol 2007;28:1320–1327.
- Vaughn C, Zhang L, Schiff D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep 2008;10:86–91.
- Ay H, Buonanno FS, Schaefer PW, . Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology 1998;51:1369–1376.
- Bartynski WS. Posterior reversible encephalopathy syndrome, Part 2: Controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol 2008;29:1043–1049.
- Connolly RM, Doherty CP, Beedy P, . Chemotherapy induced reversible posterior leukoencephalopathy syndrome. Lung Cancer 2007;56:459–463.
- Bartynski WS, Boardman JF, Zeigler ZR, . Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. Am J Neuroradiol 2006;27:2179–2190.
- Bartynski WS, Upadhyaya AR, Boardman JF. Posterior reversible encephalopathy syndrome and cerebral vasculopathy associated with influenza A infection: report of a case and review of the literature. J Comput Assist Tomogr 2009;33:917–922.
- Tam CS, Galanos J, Seymour JF, . Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic maligancies. Am J Hematol 2004;77:72–76.
- Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006;63:1475–1478.
- Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980–981.
- Mitsiades N, Mitsiades CS, Poulaki V, . Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99: 4525–4530.
- Yabu T, Tomimoto H, Taguchi Y, . Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 2005;106:125–134.
- Pandey R, Patel A, Shah S, . A rare complication in a case of multiple myeloma on therapy with thalidomide and dexamethasone—reversible posterior lobe leukoencephalopathy. Leuk Lymphoma 2006;47:1431–1434.
- Lebrun C, Chanalet S, Frenay M, . Leukoencephalopathy in multiple myeloma: two case reports. Ann Oncol 1999;10:1515–1517.